Advertisement

Journal of Community Genetics

, Volume 9, Issue 3, pp 209–215 | Cite as

From the laboratory to the clinic: sharing BRCA VUS reclassification tools with practicing genetics professionals

  • Bianca M. Augusto
  • Paige Lake
  • Courtney L. Scherr
  • Fergus J. Couch
  • Noralane M. Lindor
  • Susan T. Vadaparampil
Original Article

Abstract

Despite ongoing research efforts to reclassify BRCA variant of uncertain significance (VUS), results for strategies to disseminate findings to genetic counselors are lacking. We disseminated results from a study on reclassification of BRCA VUS using a mailed reclassification packet including a reclassification guide, patient education aid, and patient letter template for patients/families with BRCA VUS. This study reports on genetic counselors’ responses to the dissemination materials. Eligible participants (n = 1015) were identified using mailing lists from professional genetics organizations. Participants were mailed a BRCA VUS reclassification packet and a return postcard to assess responses to the materials. Closed-ended responses were analyzed using descriptive statistics, and thematic analysis was conducted on open-ended responses. In response to the mailing, 128 (13.0%) genetic counselors completed and returned postcards. The majority of respondents (n = 117; 91.4%) requested the patient letter template and patient education guides as PDFs (n = 122; 95.3%). The majority (n = 123; 96.9%) wanted an updated reclassification guide upon availability. Open-ended responses demonstrate the material was well-received; some specified they would tailor the patient letter to fit their practice and patients’ needs. Participants requested additional patient and provider educational materials for use in practice. Materials communicating BRCA VUS reclassification updates were liked and were likely to be used in practice. To achieve the benefits of VUS reclassification in clinical practice, ongoing efforts are needed to continuously and effectively disseminate findings to providers and patients.

Keywords

Genetic counseling Genetic testing Variant of uncertain significance (VUS) VUS reclassification Hereditary cancer Patient education 

Notes

Funding information

This work was supported by the Breast Cancer Spore CA 116201. This work was supported in part by the Survey Methods Core Facility at the H. Lee Moffitt Cancer Center & Research Institute; a National Cancer Institute designated Comprehensive Cancer Center (P30-CA76292).

Compliance with ethical standards

Conflict of interest

Authors Augusto, Lake, Scherr, Lindor, and Couch declare that they have no conflict of interest. Author Vadaparampil has a research grant from Myriad Genetics Laboratories.

Human studies and informed consent

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5). Prior to conducting this study, approval was obtained from the University of South Florida and Mayo Clinic IRBs.

Supplementary material

12687_2017_343_MOESM1_ESM.docx (240 kb)
ESM 1 (DOCX 239 kb)
12687_2017_343_MOESM2_ESM.docx (184 kb)
ESM 2 (DOCX 184 kb)
12687_2017_343_MOESM3_ESM.docx (162 kb)
ESM 3 (DOCX 161 kb)

References

  1. Baker DL, Eash T, Schuette JL, Uhlmann WR (2002) Guidelines for writing letters to patients. J Genet Couns 11(5):399–418CrossRefPubMedGoogle Scholar
  2. Balmaña J, Digiovanni L, Gaddam P, Walsh MF, Joseph V, Stadler ZK et al (2016) Conflicting interpretation of genetic variants and cancer risk by commercial laboratories as assessed by the Prospective Registry of Multiplex Testing. J Clin Oncol 34:4071–4078CrossRefPubMedPubMedCentralGoogle Scholar
  3. Braun V, Clarke V (2006) Using thematic analysis in psychology. Qual Res Psychol 3(2):77–101CrossRefGoogle Scholar
  4. Brown E, Skinner M, Ashley S, Reed K, Dixon SD (2016) Assessment of the readability of genetic counseling patient letters. J Genet Couns 25(3):454–460Google Scholar
  5. Campeau PM, Foulkes WD, Tischkowitz MD (2008) Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet 124(1):31–42CrossRefPubMedGoogle Scholar
  6. Cho YI, Johnson TP, VanGeest JB (2013) Enhancing surveys of health care professionals: a meta-analysis of techniques to improve response. Eval Health Prof 36(3):382–407CrossRefPubMedGoogle Scholar
  7. Cragun D, Radford C, Dolinsky J, Caldwell M, Chao E, Pal T (2014) Panel-based testing for inherited colorectal cancer: a descriptive study of clinical testing performed by a US laboratory. Clin Genet 86(6):510–520CrossRefPubMedPubMedCentralGoogle Scholar
  8. Dillman DA (2000) Mail and internet surveys: the tailored design method (vol. 2). Wiley, New YorkGoogle Scholar
  9. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C et al (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304(9):967–975CrossRefPubMedPubMedCentralGoogle Scholar
  10. Eccles B, Copson E, Maishman T, Abraham J, Eccles D (2015a) Understanding of BRCA VUS genetic results by breast cancer specialists. BMC Cancer 15(1):1CrossRefGoogle Scholar
  11. Eccles DM, Mitchell G, Monteiro ANA, Schmutzler R, Couch FJ, Spurdle AB, Gómez-García EB, on behalf of the ENIGMA Clinical Working Group, Driessen R, Lindor NM, Blok MJ, Moller P, de la Hoya M, Pal T, Domchek S, Nathanson K, Van Asperen C, Diez O, Rheim K, Stoppa-Lyonnet D, Parsons M, Goldgar D (2015b) BRCA1 and BRCA2 genetic testing—pitfalls and recommendations for managing variants of uncertain clinical significance. Ann Oncol 26(10):2057–2065.  https://doi.org/10.1093/annonc/mdv278
  12. Forrest LE, Delatycki MB, Curnow L, Skene L, Aitken M (2010) Genetic health professionals and the communication of genetic information in families: practice during and after a genetic consultation. Am J Med Genet A 152(6):1458–1466Google Scholar
  13. Gage M, Wattendorf D, Henry L (2012) Translational advances regarding hereditary breast cancer syndromes. J Surg Oncol 105(5):444–451CrossRefPubMedGoogle Scholar
  14. Grann VR, Patel PR, Jacobson JS, Warner E, Heitjan DF, Ashby-Thompson M et al (2011) Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers. Breast Cancer Res Treat 125(3):837–847CrossRefPubMedGoogle Scholar
  15. Kindig DA, Panzer A, Nielsen-Bohlman L (2004) Health literacy: a prescription to end confusion. Institutes of Medicine, Washington, DC, p 309283329Google Scholar
  16. Krippendorff K (2012) Content analysis: an introduction to its methodology. Sage, Thousand OaksGoogle Scholar
  17. Kurian AW, Hare EE, Mills MA, Kingham KE, McPherson L, Whittemore AS et al (2014) Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol 32(19):2001–2009CrossRefPubMedPubMedCentralGoogle Scholar
  18. Kutner M, Greenburg E, Jin Y, Paulsen C (2006) The health literacy of America’s adults: results from the 2003 National Assessment of Adult Literacy. NCES 2006-483. National Center for Education Statistics, p 76. https://eric.ed.gov/?id=ED493284
  19. Lindor NM, Guidugli L, Wang X, Vallée MP, Monteiro AN, Tavtigian S et al (2012) A review of a multifactorial probability-based model for classification of BRCA1 and BRCA2 variants of uncertain significance (VUS). Hum Mutat 33(1):8–21CrossRefPubMedGoogle Scholar
  20. Lindor NM, Goldgar DE, Tavtigian SV, Plon SE, Couch FJ (2013) BRCA1/2 sequence variants of uncertain significance: a primer for providers to assist in discussions and in medical management. Oncologist 18(5):518–524CrossRefPubMedPubMedCentralGoogle Scholar
  21. Maxwell KN, Wubbenhorst B, D’Andrea K, Garman B, Long JM, Powers J et al (2014) Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer. Genet Med 17(8):630–638CrossRefPubMedPubMedCentralGoogle Scholar
  22. McMaster HS, LeardMann CA, Speigle S, Dillman DA (2017) An experimental comparison of web-push vs. paper-only survey procedures for conducting an in-depth health survey of military spouses. BMC Med Res Methodol 17(1):73CrossRefPubMedPubMedCentralGoogle Scholar
  23. Mendes Á, Paneque M, Sousa L, Clarke A, Sequeiros J (2016) How communication of genetic information within the family is addressed in genetic counselling: a systematic review of research evidence. Eur J Hum Genet 24(3):315–325CrossRefPubMedGoogle Scholar
  24. Mesters I, Ausems A, De Vries H (2005) General public’s knowledge, interest and information needs related to genetic cancer: an exploratory study. Eur J Cancer Prev 14(1):69–75CrossRefPubMedGoogle Scholar
  25. Molster C, Charles T, Samanek A, O’Leary P (2008) Australian study on public knowledge of human genetics and health. Public Health Genomics 12(2):84–91CrossRefPubMedGoogle Scholar
  26. NSGC (2016) Survey report: 2016 NSGC professional status survey executive summary. National Society of Genetic Counselors. https://www.nsgc.org/p/cm/ld/fid=68
  27. O’Neill SC, Rini C, Goldsmith RE, Valdimarsdottir H, Cohen LH, Schwartz MD (2009) Distress among women receiving uninformative BRCA1/2 results: 12-month outcomes. Psycho-Oncology 18(10):1088–1096CrossRefPubMedPubMedCentralGoogle Scholar
  28. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H et al (2005) BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 104(12):2807–2816CrossRefPubMedGoogle Scholar
  29. Pepin MG, Murray ML, Bailey S, Leistritz-Kessler D, Schwarze U, Byers PH (2015) The challenge of comprehensive and consistent sequence variant interpretation between clinical laboratories. Genet Med 18:20–24CrossRefPubMedGoogle Scholar
  30. Petrucelli N, Lazebnik N, Huelsman KM, Lazebnik RS (2002) Clinical interpretation and recommendations for patients with a variant of uncertain significance in BRCA1 or BRCA2: a survey of genetic counseling practice. Genet Test 6(2):107–113CrossRefPubMedGoogle Scholar
  31. Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS et al (2008) Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 29(11):1282CrossRefPubMedPubMedCentralGoogle Scholar
  32. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17(5):405–423CrossRefPubMedPubMedCentralGoogle Scholar
  33. Richter S, Haroun I, Graham T, Eisen A, Kiss A, Warner E (2013) Variants of unknown significance in BRCA testing: impact on risk perception, worry, prevention and counseling. Ann Oncol 24(suppl 8):viii69–viii74CrossRefPubMedGoogle Scholar
  34. Roggenbuck J, Temme R, Pond D, Baker J, Jarvis K, Liu M et al (2015) The long and short of genetic counseling summary letters: a case–control study. J Genet Couns 24(4):645–653CrossRefPubMedGoogle Scholar
  35. Sandberg EH, Sharma R, Sandberg WS (2012) Deficits in retention for verbally presented medical information. J Am Soc Anesthesiol 117(4):772–779CrossRefGoogle Scholar
  36. Scherr CL, Lindor NM, Malo T, Couch FJ, Vadaparampil S (2015a) Genetic counselors’ practices and confidence regarding variant of uncertain significance results and reclassification from BRCA testing. Clin Genet 88(6):523–529CrossRefPubMedPubMedCentralGoogle Scholar
  37. Scherr CL, Lindor NM, Malo TL, Couch FJ, Vadaparampil ST (2015b) A preliminary investigation of genetic counselors’ information needs when receiving a variant of uncertain significance result: a mixed methods study. Genet Med 17:739–746CrossRefPubMedPubMedCentralGoogle Scholar
  38. Treacy K, Elborn JS, Rendall J, Bradley JM (2008) Copying letters to patients with cystic fibrosis (CF): letter content and patient perceptions of benefit. J Cyst Fibros 7(6):511–514CrossRefPubMedGoogle Scholar
  39. Tung N, Battelli C, Allen B, Kaldate R, Bhatnagar S, Bowles K et al (2015) Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer 121(1):25–33CrossRefPubMedGoogle Scholar
  40. Vail PJ, Morris B, van Kan A, Burdett BC, Moyes K, Theisen A et al (2015) Comparison of locus-specific databases for BRCA1 and BRCA2 variants reveals disparity in variant classification within and among databases. J Community Genet 6(4):351–359CrossRefPubMedPubMedCentralGoogle Scholar
  41. Vos J, Otten W, van Asperen C, Jansen A, Menko F, Tibben A (2008) The counsellees’ view of an unclassified variant in BRCA1/2: recall, interpretation, and impact on life. Psycho-Oncology 17(8):822–830CrossRefPubMedGoogle Scholar
  42. Vos J, Gómez-García E, Oosterwijk JC, Menko FH, Stoel RD, van Asperen CJ et al (2012) Opening the psychological black box in genetic counseling. The psychological impact of DNA testing is predicted by the counselees’ perception, the medical impact by the pathogenic or uninformative BRCA1/2-result. Psycho-Oncology 21(1):29–42CrossRefPubMedGoogle Scholar
  43. White P, Singleton A, Jones R (2004) Copying referral letters to patients: the views of patients, patient representatives and doctors. Patient Educ Couns 55(1):94–98CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  1. 1.Department of Health Outcomes and BehaviorMoffitt Cancer CenterTampaUSA
  2. 2.Department of Communication StudiesNorthwestern UniversityEvanstonUSA
  3. 3.Department of Laboratory Medicine and PathologyMayo ClinicRochesterUSA
  4. 4.Department of Health Sciences ResearchMayo ClinicScottsdaleUSA

Personalised recommendations